Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 1997

View Archived Issues

Abbott's newest dopaminergic compounds described in patent literature

5-HT4 antagonists disclosed by Taisho

Cephems in development at Meiji Seika

Cell migration inhibitors from Teijin

Japanese researchers develop new HIV protease inhibitors

Magainin analogues reported by Scripps

Pollakiuria treatment described by SS Pharm.

Tanabe Seiyaku discloses novel antinephritic compounds

Egis develops 5-LO inhibitors

Antitumor prodrugs for ADEPT from Pharmachemie

BTG describes immunosuppressive antibodies

BASF discloses antithrombotic from ticks

Lilly/Novo Nordisk discover candidate for IBS

Clinical trial data reported for meningitis vaccine

Another approval for first-line Abelcet

Hemosol discloses novel cellular immunotherapeutic procedure

Genzyme acquires PharmaGenics and forms new division

LifeTECH and Pall announce collaboration

Abgenix reports significant advance in human antibody technology

First Corlopam Renal Program study completed

Access/Dow collaborate on contrast agents and radiopharmaceuticals

Sugen's TK antagonist enters phase II

Antiobesity agent from Neurogen/Pfizer advances to multiple-dose trials

Whole-body hyperthermia therapy enters clinic for new indication

FDA approval for Ferring antifertility Rx

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...